Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
varicella vaccine (Research Foundation for Microbial Diseases of Osaka University)
- Development stage
- Approved
- Lead developer
- Research Foundation for Microbial Diseases of Osaka University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The live attenuated varicella zoster virus vaccine is a biologic product derived from the Oka strain of the varicella-zoster virus (VZV). Traditionally used for the prevention of varicella (chickenpox) and herpes zoster (shingles), it is being investigated as an unconventional immunotherapy for hematologic malignancies. Developed and manufactured by the Research Foundation for Microbial Diseases of Osaka University (BIKEN), the vaccine is administered to induce antitumor immunity in patients with adult T-cell leukemia/lymphoma (ATLL), chronic myelogenous leukemia (CML), and myelodysplastic syndromes (MDS). The proposed mechanism involves the stimulation of VZV-specific memory T cells, which may enhance the recruitment and activation of tumor-specific cytotoxic T lymphocytes (CTLs), such as HTLV-1 Tax-specific CTLs in ATLL patients, thereby providing a therapeutic effect against the underlying malignancy.
- Brand names
- Varicella Vaccine BIKENVarivaxVarilrixZostavax
- Other names
- live attenuated varicella zoster virus vaccineVZV vaccineOka strain varicella vaccinezoster vaccine live
02
Targets
gE (VZV glycoprotein E)IDE (Insulin-degrading enzyme)
Beyond the preview
Go deeper on varicella vaccine (Research Foundation for Microbial Diseases of Osaka University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on varicella vaccine (Research Foundation for Microbial Diseases of Osaka University).